Cart
sales@molnova.com
BAY 2965501
CAS No. 2732902-08-6
BAY 2965501( —— )
Catalog No. M36493 CAS No. 2732902-08-6
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor that induces pERK activation, and it can be utilized in cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 128 | Get Quote |
|
| 5MG | 188 | Get Quote |
|
| 10MG | 353 | Get Quote |
|
| 25MG | 634 | Get Quote |
|
| 50MG | 821 | Get Quote |
|
| 100MG | 1107 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBAY 2965501
-
NoteResearch use only, not for human use.
-
Brief DescriptionBAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor that induces pERK activation, and it can be utilized in cancer research.
-
DescriptionBAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetPERK
-
RecptorPERK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2732902-08-6
-
Formula Weight414.45
-
Molecular FormulaC20H19FN4O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (241.28 mM)
-
SMILESN([C@@H](C(N)=O)C)(C=1SC(C(=O)C2=CC=C(OC)C=C2)=C(N)N1)C3=CC=C(F)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schubert N, et al. Phosphorylated extracellular signal-regulated kinase (pERK) activation in T effector cells as a target engagement biomarker for the DGKζ inhibitor BAY2965501 in clinical trials. Cancer Research, 2023, 83(7_Supplement): 2116-2116.
molnova catalog
related products
-
Rineterkib
Rineterkib is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.
-
rac-BHFF
Rac-BHFF is potent and selective GABA B receptor positive allosteric modulator that increases the potency and efficacy of GABA ( > 15-fold and > 149% respectively).
-
CCT020312
CCT020312 (0-9 μM, 24 h) treatment of medium HT29 cells for 24 h resulted in a concentration-dependent loss of P-S608-pRB signaling with linear response values between 1.8 and 6.1 μM.
